Growth differentiation factor 15 (GDF15) elevation in children with newly diagnosed cancer.

Runco DV, DiMeglio LA, Vanderpool CP, Han Y, Daggy J, Kelley MM, Mikesell R, Zimmers TA. Growth differentiation factor 15 (GDF15) elevation in children with newly diagnosed cancer. Frontiers in oncology. 2023 Dec 11; 13:1295228.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: Growth differentiation factor 15 (GDF15), an inflammatory marker and mediator of adult cancer cachexia, remains largely unexplored in children. GDF15 increases nausea, vomiting, and anorexia in cancer and contributes to malnutrition, with the potential to be a cachexia therapeutic target. No studies have examined GDF15 in children with newly diagnosed cancer. Our pilot study compares GDF15 in children with newly diagnosed cancer to age- and sex-matched controls and correlates levels with anthropometric measurements and quality of life (QOL). METHODS: Children with newly diagnosed cancer aged 2-21 years were enrolled with serum GDF15 ELISA, anthropometric measures [height, weight, and mid-upper arm circumference (MUAC)], and QOL assessments (using PedsQL Core and Gastrointestinal Modules), which were collected at baseline and repeated 3 months later. Serum GDF15 levels were obtained from age- and sex-matched controls for comparison. RESULTS: A total of 57 participants enrolled (N = 30, cancer group; N = 27, control group) with a median age of 8.8 years (IQR 5.6-15.9 years). The participants were primarily male (54.4%), white (82.5%), and non-Hispanic (82.5%). Cancer diagnoses included acute lymphoblastic leukemia (N = 8), lymphoma (N = 8), neuroblastoma (N = 5), soft tissue tumors (N = 4), acute myeloid leukemia (N = 2), and single participants with brain, kidney, and bone tumors. Baseline GDF15 was higher in the cancer cohort compared to the control cohort (median = 614.6pg/mL and 320.5pg/mL, respectively; p < 0.001). When examining participants with evaluable baseline and 3-month follow-up GDF15 levels (N = 18), GDF15 was not statistically different (median = 657.1pg/mL and 675.3pg/mL, respectively; p = 0.702). A total of 13 of the 30 participants and 21 caregivers completed the PedsQL Core and Gastrointestinal symptom modules. QOL scores did not differ significantly at 3-month follow-up compared to baseline, but diarrhea worsened (p = 0.017). Median participant response for diarrhea at baseline was 92.9 (IQR = 92.9-96.4; N = 13), which was significantly better than the follow-up (median = 78.6; IQR = 71.4-92.9; p = 0.017). There were no correlations between change in height, weight, or MUAC and change in GDF15 levels (p = 0.351, 0.920, and 0.269 respectively). CONCLUSION: GDF15 was elevated in children with cancer at diagnosis compared to controls but did not correlate with anthropometric measurements or QOL. This pilot study will inform future prospective studies to better describe the natural history of GDF15 and its role in cachexia and as a potential therapeutic target.